Overview of Avsartan

Property	Description
Active Ingredient	Irbesartan
Form	Oral film-coated tablet
Pharmacological Class	Angiotensin II Receptor Blocker (ARB)
General Purpose	Management of high blood pressure
Origin	Synthetic compound

Avsartan is a prescription medication designed to help manage blood pressure. It is specifically classified as a single-ingredient product (monotherapy), meaning its therapeutic action relies entirely on its core chemical component. The drug is typically utilized in therapeutic settings that require long-term, systematic control of vascular tone.

What Type of Medicine is Avsartan?

Avsartan belongs to the class of cardiovascular agents known as Angiotensin II Receptor Blockers (ARBs), or AT₁ Receptor Antagonists. The active substance in Avsartan is Irbesartan, a synthetic, non-peptide compound chemically characterized as a biphenylyltetrazole. The primary action of Irbesartan is to inhibit the effects of the potent, naturally occurring hormone Angiotensin II. This mechanism is widely recognized in clinical practice for its reliable effect in managing the Renin-Angiotensin System.

Composition and Physical Form of Irbesartan

Avsartan is formulated for oral administration and is supplied as an oral, film-coated tablet. The primary therapeutic component is Irbesartan, which does not require significant biotransformation to become active upon ingestion. As a monotherapy, this preparation contains only Irbesartan and uses solid pharmaceutical excipients to create a stable dosage form suitable for consistent intake. Irbesartan has been clinically recognized for its high systemic bioavailability compared to some other members of the sartans class, supporting its efficacy through oral dosing.

What is the General Purpose of Avsartan?

Irbesartan's general purpose is to modulate the body's natural system for regulating vessel tone, thereby lowering high blood pressure. This effect is achieved through the highly selective antagonism of the potent vasoconstrictor hormone Angiotensin II at its AT₁ receptors. By interrupting this signal, Irbesartan allows the blood vessels to relax and widen, a process known as vasodilation. This physiological action provides the general benefit of reducing the sustained force exerted against the arterial walls, which decreases systemic vascular resistance and lessens the chronic workload placed on the heart.

Regulatory References

European Public Assessment Report (EPAR) for Aprovel (Irbesartan)

What side effects are possible with Avsartan?

Possible Side Effects and Safety Information: Avsartan

Avsartan (irbesartan) is an angiotensin II receptor blocker (ARB) associated with a known profile of adverse reactions primarily related to its effect on the renin-angiotensin system (RAS).

Common and Serious Adverse Reactions

Commonly reported side effects (occurring in ge 1/100 patients) include headache, dizziness or lightheadedness (vertigo), and fatigue or unusual weakness. Gastrointestinal effects such as nausea, vomiting, and diarrhea may also occur.

Serious or clinically significant adverse reactions, which require immediate medical attention, include:

Fetal Toxicity: Use during the second and third trimesters of pregnancy can cause injury or death to the fetus, leading to a major regulatory warning. Discontinuation is advised immediately upon detection of pregnancy.
Angioedema: Swelling of the face, lips, throat, and/or tongue, which may cause difficulty breathing or swallowing (a severe hypersensitivity reaction).
Hypotension: Symptomatic low blood pressure, especially in patients who are volume- or salt-depleted.
Impaired Renal Function: Changes in kidney function, including acute renal failure, particularly in susceptible patients (e.g., those with severe heart failure or renal artery stenosis).
Hyperkalemia: High levels of potassium in the blood, often requiring serum potassium monitoring, particularly in patients with kidney impairment or those taking potassium-sparing agents.

Population-Specific Safety Considerations

Population	Safety Consideration
Pregnancy	Contraindicated in the second and third trimesters due to fetal toxicity.
Dual RAAS Blockade	Contraindicated with aliskiren in patients with diabetes or moderate-to-severe renal impairment.
Volume/Salt Depletion	Requires caution and may necessitate correction before initiation to minimize symptomatic hypotension risk.

Close monitoring of renal function and serum electrolytes (potassium) is recommended for patients at risk due to pre-existing conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary documented signs and symptoms associated with an overdose of Avsartan (irbesartan) are those related to pronounced low blood pressure (hypotension).

Documented Overdose Presentations: The most likely effects reported are feelings of light-headedness and dizziness. Overdose may also present with changes in heart rate, such as a fast heartbeat (tachycardia) or, less commonly, a slowed heartbeat (bradycardia).
Required Emergency Action: Taking too many Avsartan tablets requires urgent medical attention. You should immediately contact emergency medical services or go to the Emergency Department at your nearest hospital.
Mandatory Warning: It is essential to seek medical help even if there are no immediate signs of discomfort or poisoning, as serious complications like profound hypotension may develop. Always bring the medication packaging or official leaflet with you to the healthcare facility.
Clinical Management Note: Treatment for an overdose is supportive, focusing on correcting the low blood pressure. Due to the active ingredient's high level of protein binding in the blood, the substance is not removable by standard procedures such as hemodialysis. Therefore, careful monitoring and supportive care are crucial in an overdose setting.

Therapeutic Uses of Avsartan

What Avsartan Treats: Main Uses and Benefits

Avsartan (Irbesartan) is generally considered relevant for managing conditions characterized by systemic imbalance, focusing on specific cardiovascular and renal health markers. It is commonly applied in clinical settings for long-term supportive symptom management.

The primary therapeutic use is relevant in contexts involving heightened systemic burden, assists with maintaining functional stability, and is commonly used to help with symptoms related to heightened physiological activity (essential hypertension). It is also commonly used to help with conditions marked by increased physiological stress, such as diabetic nephropathy in patients with Type 2 diabetes, where it supports the management of symptom clusters that create noticeable physiological strain.

Avsartan is applied in addressing situations where symptoms related to irritative states (e.g., persistent cough) affect stability, offering an alternative for individuals with high blood pressure. This overall therapeutic approach contributes to easing the overall symptom load associated with chronic physiological strain.

Quick Fact: Relief for Systemic Imbalance

Avsartan is relevant for easing symptoms that create noticeable physiological strain, primarily by managing sustained high blood pressure and supporting renal health in the context of diabetes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Avsartan?

Avsartan (Irbesartan) eligibility is defined by regulatory guidelines that categorize patient populations into those who are allowed, restricted, or contraindicated from using the medicine.

Allowed Populations

Use is established for adults with hypertension and diabetic nephropathy. For pediatric use, the medicine is approved for children six years of age and older for the treatment of hypertension. Older adults typically do not require dosage adjustments.

Absolute Contraindications

Avsartan is contraindicated in patients with a history of hypersensitivity to the active substance or excipients. Its use is strictly prohibited during the second and third trimesters of pregnancy due to fetal risk. It is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73m²) who are concurrently using aliskiren-containing products.

Restricted and Conditional Use

Use is not recommended during the first trimester of pregnancy or while breastfeeding. Special caution is required in patients who are volume- or salt-depleted (which may necessitate a lower starting dose) and those with conditions like renal artery stenosis or severe heart failure where renal function is closely tied to the body's vascular system.

What should I know about interactions with other medicines?

Avsartan (irbesartan) can interact with several other medicines and substances, which may increase the risk of side effects, particularly affecting blood pressure, electrolyte balance, or kidney function. It is important to inform your doctor about all prescription and non-prescription drugs, vitamins, and herbal supplements you are currently taking.

Key interactions that require careful monitoring or dose adjustment include:

Increased Risk of High Potassium and Kidney Issues

Co-administering Avsartan with certain medicines or products can lead to hyperkalemia (high potassium levels) or increased risk of kidney damage. Close monitoring is essential if you are taking:

Potassium-sparing diuretics (e.g., spironolactone, amiloride)
Potassium supplements or salt substitutes that contain potassium
Other Angiotensin II Receptor Blockers (ARBs), ACE inhibitors (e.g., lisinopril, enalapril), or aliskiren
Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including common pain relievers like ibuprofen and naproxen, especially in elderly or dehydrated patients, or those with existing kidney impairment.

Other Significant Interactions

Interacting Product	Potential Effect
Lithium (used for mental health)	Avsartan may increase lithium levels, leading to increased toxicity.
Antidiabetic medicines (e.g., repaglinide)	Avsartan may increase the effects of these drugs, raising the risk of low blood sugar (hypoglycemia).

Simultaneous use of Avsartan with other blood pressure-lowering agents may lead to an excessive drop in blood pressure (hypotension).

Mechanism of Action

Targeted Blockade of the AT1 Receptor

Avsartan operates primarily as a selective antagonist by directly engaging the Angiotensin II type 1 ( AT1) receptor. This receptor is a key biological target within the Renin-Angiotensin System (RAS) cascade. By binding to the AT1 receptor, Avsartan competitively prevents the vasoconstricting hormone Angiotensin II from attaching and initiating its signaling sequence. This blockade effectively suppresses the activation of the receptor by its endogenous ligand.

Downstream Physiological Modulation

Intervention at this specific point in the cascade modifies the downstream signaling sequence related to vascular tone and fluid balance. Limiting the AT1 receptor activation by Angiotensin II reduces the AT1-mediated contractile signal to vascular smooth muscle. This action also alters the feedback regulation within the targeted pathways, leading to the modification of aldosterone release and systemic fluid handling. The mechanism focuses entirely on modulating specific receptor-mediated responses within the cardiovascular regulatory system.

Dosage and Administration Information

Official Administration Guidelines for Avsartan (Irbesartan)

Avsartan (Irbesartan) is an angiotensin II receptor antagonist provided in oral tablet form, with strengths of 75 mg, 150 mg, and 300 mg. The instructions for its use must be followed precisely to ensure intended therapeutic management.

Dosing and Schedule

Usage Context	Initial Recommended Dose	Maximum Daily Dose
Standard	150 mg once daily	300 mg once daily
Volume/Salt Depletion	75 mg once daily	300 mg once daily
Type 2 Diabetic Nephropathy	300 mg once daily	300 mg once daily

The tablets are to be taken once daily at approximately the same time each day to maintain a consistent effect.

Administration Method and Special Instructions

Method: The tablet must be swallowed whole with water.
Food: Administration may occur with or without food.
Pediatric Use: Safety and efficacy have not been established in children under 6 years of age.
Elderly: Consideration may be given to initiating therapy with 75 mg in patients over 75 years of age.
Missed Dose: If a dose is missed, it should be taken as soon as remembered; however, if it is close to the time for the next scheduled dose, the missed dose should be skipped. Patients must not take a double dose to compensate for a missed one.
Dose Adjustment: A lower starting dose of 75 mg once daily is specifically recommended for patients with uncorrected salt/volume depletion (e.g., those on hemodialysis).

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Phase 2/3 Clinical Research

Research on this investigational compound has included both Phase 2 and Phase 3 randomized controlled trials (RCTs). These studies evaluated the safety profile and explored the investigational compound's effect on various disease markers in adult patients.

Key Trial 1: Monotherapy vs. Placebo

Study Design: A multi-center Phase 3 RCT involving 1,200 participants.
Primary Focus: Research explored whether the investigational compound was associated with a reduction in pain and stiffness in participants with moderate-to-severe disease.
Findings (Neutral Summary): The study reported on a change in pain scores at 12 weeks compared to baseline. Secondary endpoints investigated potential changes in joint function, quality of life metrics, and biomarkers of inflammation. Study participants were advised to avoid co-ingestion with alcohol during the trial period.

Key Trial 2: Combination Therapy

Study Design: A Phase 2 trial examining the investigational compound in combination with an existing standard-of-care drug.
Primary Focus: The primary goal was to see if the combination affected the primary outcome, which was a pre-specified clinical response rate at 24 weeks.
Findings (Neutral Summary): Differences in outcomes between the combination and monotherapy were examined, with results reported on in the study publication. The studies examined whether the investigational compound was associated with a reduction in biomarkers of inflammation. Overall, the trials evaluated the safety profile of the investigational compound under various dosing regimens.

Summary of Outcomes

The evidence is derived solely from the results reported from the Phase 2 and Phase 3 clinical trials. It is not yet clear whether the investigational compound affected long-term outcomes compared to existing treatments.

Key Studies & References NICE Guideline: Management of Chronic Inflammatory Conditions (Referencing JAK Inhibitors)

Frequently Asked Questions (FAQ)

Common questions about Avsartan (FAQ)

Q: How quickly does Avsartan start working to lower blood pressure?

Regulatory documents state that a blood pressure-lowering effect is apparent after the first dose of Avsartan. This medicine begins working shortly after starting treatment.

Q: How long after starting Avsartan will I experience the full effect?

According to the official product information, the medicine is generally close to its full observed effect at two weeks of treatment. The maximum benefit in managing blood pressure is typically achieved after a short period of consistent use.

Q: Can Avsartan cause a dry, persistent cough like some other blood pressure medicines?

Official reports indicate that Avsartan use was not associated with an increased incidence of dry cough in clinical trials. This specific side effect is typically noted with a different class of blood pressure medications called ACE inhibitors.

Q: Does Avsartan interact with common over-the-counter pain relievers, like NSAIDs?

Regulatory documents describe that taking Avsartan with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers, may increase the risk of hyperkalemia (high potassium levels) and kidney problems. This combination may require monitoring by a healthcare provider.

Q: Are there specific vitamins or herbal supplements that are known to interact with Avsartan?

Official product information notes that the use of Avsartan with potassium supplements or salt substitutes that contain potassium may increase the risk of high potassium in the blood. If supplements are used, official information indicates awareness of the potassium content is relevant.

Q: What blood tests or monitoring will be needed while taking Avsartan?

Close monitoring of renal function (kidney tests) and serum potassium levels is recommended while taking Avsartan. Monitoring by a healthcare provider is generally recommended, particularly for patients at risk due to other conditions.

Q: What is the official information regarding Avsartan use during pregnancy?

Avsartan is contraindicated (prohibited) for use during the second and third trimesters of pregnancy due to the risk of injury and death to the fetus. Use during the first trimester is not recommended.

Q: What is the official information regarding Avsartan use while breastfeeding?

According to official regulatory documents, use of Avsartan is not recommended while breastfeeding.

Q: Is it normal to not 'feel' any different after starting Avsartan for high blood pressure?

High blood pressure is a condition that often has no symptoms, so it is normal for many people to not feel an immediate physical change after starting this medicine. However, some people may notice common side effects, such as a headache or dizziness.

Q: Does Avsartan have an effect on kidney function?

Avsartan is indicated to treat diabetic nephropathy (kidney disease) in certain patients. Conversely, official warnings note that in patients with certain pre-existing conditions (e.g., severe heart failure), a decrease in renal function (kidney function) has been described as a risk, requiring careful monitoring.

Q: Is there a risk of high potassium (hyperkalemia) when taking Avsartan?

Official documents state that high levels of potassium in the blood, known as hyperkalemia, may occur. This is a potential risk, particularly for patients with existing kidney impairment or heart failure.

Q: Do official documents mention any potential for Avsartan to cause swelling (angioedema)?

Angioedema, which is serious swelling of the face, lips, throat, and/or tongue, is reported as a rare but serious adverse reaction. This condition requires immediate medical attention.

Q: What is the risk of having low blood pressure (hypotension) with Avsartan?

Symptomatic low blood pressure, called hypotension, is listed as a potential risk of taking Avsartan. This risk is noted to be higher in patients who are volume- or salt-depleted.

Q: Can Avsartan be taken at any time of day, or is one time better?

The medicine is to be taken once daily at approximately the same time each day to maintain a consistent effect. Regulatory information does not specify a preferred time of day, such as morning or evening.

Q: Is Avsartan a 'life-long' medication, or can I stop taking it once my blood pressure is lower?

Avsartan is indicated for the treatment of chronic conditions like high blood pressure. Any changes to medication use are subject to medical guidance, as blood pressure may increase again once the medicine’s effects wear off.

Q: Can I drink alcohol while taking Avsartan?

Regulatory documents indicate that alcohol may increase the risk of side effects like dizziness or lightheadedness, which are also known potential effects of Avsartan. Official information indicates the potential for combined effects.

Q: How should Avsartan tablets be stored?

Avsartan tablets should be stored at controlled room temperature (e.g., 68 F to 77 F) and kept away from light and moisture. It is officially required to secure the medicine out of the reach of children.

Q: What is the difference between Avsartan and Avsartan HCT?

Avsartan contains the single active ingredient, Irbesartan. Avsartan HCT is a separate combination product that contains Irbesartan and Hydrochlorothiazide, which is a diuretic or 'water pill'.

Q: Is Avsartan generally considered safe to take for long periods of time?

The medicine is indicated for the treatment of chronic conditions, and its safety profile is explored through long-term clinical studies. The official product information provides details on all known risks and adverse events.

Q: What are the main things I should tell my healthcare provider before starting Avsartan?

Official documents outline that health history relevant to the medicine includes: pregnancy or breastfeeding status, existing kidney or liver conditions, any state of salt- or volume-depletion, and use of other medicines that affect blood pressure regulation (like an ACE inhibitor) or may raise potassium.

Q: Is Avsartan indicated to reduce the progression of kidney disease in patients with high blood pressure?

In hypertensive patients with Type 2 diabetes and nephropathy, official documents indicate that Avsartan reduces the rate of progression of kidney disease. This is measured by the occurrence of doubling of serum creatinine or end-stage renal disease.

Q: Why is Avsartan sometimes preferred over other blood pressure medications?

Avsartan belongs to the Angiotensin II Receptor Blocker (ARB) class, which works by selectively blocking the AT1 receptor. Unlike ACE inhibitors, ARBs do not inhibit the enzyme ACE, which means they do not interfere with the breakdown of certain natural substances in the body, which is related to the absence of cough.

Q: Can Avsartan affect my ability to drive or operate machinery?

The potential for side effects, such as dizziness or fatigue, may affect the ability to safely drive or operate heavy machinery. Official documents recommend caution based on these known effects.

Q: What kind of research has been done on Avsartan's long-term effects?

Regulatory documents refer to multiple major placebo-controlled, double-blind trials and long-term extension phases. These studies explored the drug's effects on blood pressure and safety profile in the treatment of hypertension and diabetic nephropathy over time.

Q: Does Avsartan have any known effects on cholesterol levels?

In clinical studies in patients with high blood pressure, there were no clinically important effects on fasting triglycerides, total cholesterol, or HDL-cholesterol concentrations.

Q: Are there different strengths or doses of Avsartan available?

Avsartan is available as oral film-coated tablets in three different strengths: 75 mg, 150 mg, and 300 mg.

Q: Can Avsartan be taken with other heart or blood pressure medications?

Official documents state that Avsartan may be administered with other antihypertensive agents. However, there are strong warnings and a contraindication against dual blockade of the body's blood pressure regulating system, such as combining it with an ACE inhibitor or aliskiren.

Q: What is the meaning of the 'Angiotensin II Receptor Antagonist' drug class?

This classification describes how the medicine works by being an antagonist (a blocker) that selectively prevents the hormone Angiotensin II from binding to and activating the AT₁ receptor in the body.

Q: Is Avsartan prescribed to patients who have heart failure?

The drug is indicated for hypertension and diabetic nephropathy. Official warnings describe that special caution and close monitoring are required for patients with severe congestive heart failure due to the potential risk of effects on kidney function.

How should Avsartan be stored and disposed of?

Official Storage and Disposal Guidelines

Avsartan (Valsartan/Amlodipine) must be stored and handled according to specific requirements established by regulatory bodies to maintain its effectiveness and ensure household safety.

Storage Requirement	Official Guideline
Temperature	Store at controlled room temperature (e.g., 20°C to 25°C / 68°F to 77°F). Do not freeze.
Environmental Protection	Keep away from heat, moisture, and direct light, and store in a dry place.
Container Integrity	Keep tablets in the original container, and ensure the container is tightly closed.
Safety	Keep the medication out of the reach of children.

For disposal, unused or expired medicine should be returned through an official drug take-back program. If a take-back program is unavailable, mix the medication with an undesirable substance (such as dirt or coffee grounds) in a sealed bag before placing it in the household trash. Do not flush this medication unless specifically instructed by the label, and ensure the product is not released into the environment.

Avsartan